Clark Henegan
@clarkhenegan
Medical Oncologist with focus in prostate, bladder, kidney and testicular cancers. Tweets reflect my personal opinion.
ID: 1124733403851644929
04-05-2019 17:51:54
782 Tweet
366 Takipçi
505 Takip Edilen
#ProstateCancer variants ✨Germline HOXB3 X285K variant: ⏩️risk factor in men of African ancestry ⏩️better response to ARPI Carlos Alberto Toledo Martínez Clovis Fraga T. Pereira OncoAlert Paulo Roberto Salustiano Dr. Rafael Mourato @MSdoNascimento Luis Fernando Sala Ana Paula Garcia Cardoso Daniel Vargas Pivato de Almeida fabio schutz @sandrocavallero
Survivor University provides resources to improve the quality of life of individuals facing cancer. In a recent expansion, the program is now open to all Mississippians, not just those treated at the University of Mississippi Medical Center. umc.edu/cancerinstitut… Rod Rocconi
Honored to announce that I’ve accepted the role of Division Director of Hem/Onc and Associate Director for Clinical Affairs at the Cancer Center, University of Mississippi! Looking forward to contributing to the team’s growth and success this fall! #lcsm UMMC Cancer Center and Research Institute Rod Rocconi
The Cancer Center and Research Institite recently hosted a community health education fair in Lexington, Mississippi, where Dr. Justin Turner spoke about cancer health in our state. Participants visited vendors and learned about resources to assist with their needs. Rod Rocconi
When you ( thoracic oncologist) are in orientation with an excellent thoracic surgeon, it’s the making of a dream team to fight and eliminate lung cancer in Mississippi! #lcsm UMMC Department of Medicine Kelsey Koch UMMC Cancer Center and Research Institute Rod Rocconi Pierre de Delva #WomeninMedicine
Matt Cooperberg National Comprehensive Cancer Network (NCCN) Amer. Urol. Assn. European Association of Urology (EAU) The next step needs to be biomarker and imaging directed stratification. Drives me crazy that risk uses the antiquated t staging based on DRE and ignores MRI findings.
🚨Just in Nature Medicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj Prostate Cancer Foundation OncoAlert UroToday.com
Field-moving data , a new-era, with #Christofvulsteke in cisplatin-ineligible MIBC. KEYNOTE-905, Ph.III, finds periop EV+pembro smashing risk (EFS HR 0.40), improving survival (OS HR 0.50), and quadrupling pCR to 57% vs 9%. #ESMO25 #BladderCancer ESMO - Eur. Oncology Annals of Oncology
We are so grateful and ready for this! 🙏 Rod Rocconi UMMC Cancer Center and Research Institute UMMC Department of Medicine UMMC raises money to build new $250M cancer center, seeks funding from Legislature mississippitoday.org/2026/01/22/umm…